Reply  by Honan, Michael B.
LETTERS TO THE EDITOR - 
Cardiac Rupture and Time to 
Thromholytic Treatment 
Serious methodologic flaws render fbc resobs and i”,erpre,aoo” of,he 
slody of Honan et al. ,I) qscsdonable. Ofrhe 42 mah selected for the 
monalily analysis. only 4 me, ,he criteria for rbe a”alyd5 of esrdiac 
rupture. In meta-analyria. seleclio” bias can oa”r when ,here are 
incomolele da:a on eveob from all wrenliallv elieible tnalr. This is 
““0,“‘ to allemp, to e.& that ;I, o”,come EY~“,S of in&n are 
col,ec,ed. This w: c not done in thi. radv. 
In the four ltiafr analyzed. Ihe oddf ratio of cardiac mptore in 
s,rep,“kinase.,rea,ed palienls varied between 0.63 and 3.8. Indlvld- 
“ally “one were stolidcally significa”,. with exrraordtnanly wde 
95% confidence intervals. Overall there acre 58 ceses of rupture. LY 
(3.5%) among s,rep,okirmsee-treated patients and 29 0.6%) among 
,he conbvl subjects. This corresponds lo a” odds redo ofO.98 195% 
confidence inrerval 0.58-1.65. lest for hererogeneily wilh 3 df = 
NS). clearly a nonsigoifica”, reso,,. A lo,&,ic regression rmalysi, 
we* Lbe” used IO dc,ermi”e if fbere wa> a” i”wrac,m” between 
roplore and lime fo treatme”,. While lis,i”c six factors beliered ,o 
increase risk of ~p,we. the aulhors did no, include these in lheir 
slalistical model. This leaves some oncenaimy as Lo the pu,sibility 
of confounding eRec,s of these six risk factors. I” addillon. the 
authors did no, ox the x,wal ,ime to ,re~men, of those patirnrs 
with rupture bu, instead used the group mea”. Give” Iheir inilial 
objective. this is a” unra,isfac,ory compromise. Again. il ponuu of 
,he orGal data should have bee” attemmed. 
RdY 
Thi, rtody was promp!ed afwr our observarw” of cardiac roplure in 
a71 ,ex old t,oman w-ho received s,reo,okinare 6 davs after L bree 
A rtarirticatty rigrdhcanl association urmg regrkon amlys~r bate&d mvwrrdia, i”larc,icn. Thrombolyue ,heopy’was ire” f& 
(however ,e”ooosI does not esWblish a causal r&lion as bnferred by bewe “&I regurgiwlion Iha, was believed 1” be polenlially 
the authors I?). Causarion reouires stric, criwia no, oddrewd bv trr‘hemlc in the oresence of ab,o,al oeclusio” of Ihe circ”mRer 
this study (31. anery wh ,hr&b”s. A, ulopsy ,hc pstie”, was found to have a 
The four lrkds selecled are no, represemawe of prev”! (lily rupture throueh P region of ,ranwwrd infarcdo” [ha, was extr~.“r- 
thrombolylir PI-71. A,, were pobbshed before 198” and wed low dinnrily hemurrha~ic. A review of published pa,hologic sludies 
dose r,rep,“ki”ase infusion regime”s not “red today. Two lnals weeesled that rhromholytic therapy promoles hemorrhage inlo ,he 
included palients up lo 71 h from the onsr, of symp,oms ,J.Sl. Two central zone of mfaraio” aDd lhat herrorrbage i”,o rebioor of 
trials did not reslric, inclusion IO pillientr \rilh definite lniarcliun tro”smoral “ecroah promoles car&c mpare. Thor we pr”po\ed 
(5.7). Moreover. in the two Irkih in which the odda rdti”, “fcardirc that lbrombolytic thenpy give” late after a~ infarc, bar already 
n&we and dealh were >,.O ,i.e., ~“rse with weo,okimwl. become tran~mural would be exoccted 10 oromole cardiac mohue: 
&;uid “se was compolrory ,451. A”&i”Ramma,ory &en!> u”d convenely. early therapy ahauld preve”, ira”rmural progression of 
particularly <@ternids in ,he selling of acole myucard”d infarction infarctlo”. and thus cardiac ropare. Thus we undcnoak our mela- 
have been associated Pilh infarct expansion and cardiac rop,ure !RI. o”alysn lwking for “” r~~c&tio” of cardiac mpwre with delay in 
The poIe”lia, confoondi”~ c,Tec, of rlerolds was “ever addrersed. the admi”i\:r”do” of thrombalytic rheropy rather ,ha” as a pas, hoc 
Theauthon USC d”,“fromtheCr”~,m ltalianuper IoStudtodella analyw nfter unsoccersfully ,ryi”g IO correlale thmmbolylic Ihe:- 
S,replochi”asi”ell‘lnfo~o MiocanlieoIGISSIl,rialarcorrobor;~,~ve dpy wh cardaac rupture in a lime-independe”, manner os ww~,cd 
evidence for this a~soci&m. This ,q uwaliafxror) as inheren, by Masrel. 
selecfioo bias in ,hc pelforroance ofautopxe~ cilnno, be excluded. Masse, reswes tha, the presence of ccRai” risk factors Br 
This IP parocularly frue when rhe me afsut”p\y ib low t 16%) Mm cardme rupture were not included in our logiilic regression model. 
impor&“,. the GlSSi ma, (i.n ““blinded! I\ it “a mar, likely that We do “a, suffes, that the risk faclors were not operative i” these 
lhasc pa,ie”,t know? 10 hwc receiwd strcptokinarc \cho die pabems. o”!y tha, the” eRecrr were aimilvrly dirtnbuled between 
soddenly will undergo a” au,op,y” ,reil,mrn, and con,ro, groups at. a res”,, of s”ccer.l”l m”dor”iz;t- 
Because “flhex method”lo& bm”i”w”~. the “uthon c”ocIu- lion. Thus. ubhin each ldal the risk faclors should no, cam? the odds 
avaikxble publi&cd dara w&me the rrequcncy of this compbcadon. 
Fhich ~counred 6~38% ofdcalbr amonepalienlr in xhom if could be 
evaluated. We arc w~lerul lo h,,” for elrboralina on some or the 
~bon~uminp~olthe\ludy. whsh wul:nolall beindodedmlheanicle 
in order 1~1 m&c the lcngtb \uitablc ror publication. While the rtudy 
fdl\,honorfulfilling Koeh’\pu,lulatelforcaulalion,we believed that 
the queaion posed r*as or vilal impmancc IO clinician, caring for 
palien& with acute myocardial mfarclion. eip-ecially ar the time 
window for we or dvomhuly+ i\ exwndcd longer arter rymplom 
onlet We bcheved dtat the suppon orbnh the mela-analysis and uhe 
GlSSldalaforoura p-i& hyporhcsir bawd oncompellingpalhophyr- 
iolo$c ob\ervationr mandad our diswmination of the findings. 
Masse1 expresses conccrn that we do no! have primary daya on 
the individual patlentr in each trial. We ;yrce wnh his suggestion 
and have rubmilled requertr ror Informan on each indwidusl 
patient 10 mve~lipalorr from the 43 randomized controlled trials for 
which autop\y rater were no, known to br <.cO%. We wspec, ,hs, 
it may be Jdiicult for us 10 locale some ofthe inveatigalon involved 
in rludie, publirbed a~ long as 31 years ago. and for them 10 
retrowctwely rcconcmxl data sets on 25.6X padcntr inclusive or 
autopsy and demographic data for US in a Us3blc maimer. We are 
more optimnlic lhal a polentielly more iwwale source or informa. 
dun may be provided by analysis of subsers of padrnn rrom the 
*aemarmnal Study or infarct Survival.2 study 11, or the *nglo. 
Scandinavian Study or Earlv Thrombolvris (2) limtled to oatienlr 
Low Dose Amiodarone in Congestive 
Heart Failure 
We read wilb p.rcat inwest the article by Hamer and others (I) and 
the editorial comments by Challerjee 12) an treating patients with 
congerli”c heir, hilure with bW dorc .miudarunc. Wa hiwc km 
udlizine amiodarune for a numberofyearr in pxicms wtb complex 
ventricular arrhythmias and low ejection fraction and have sign& 
canlly decreered Ihe complexity or Ihe iarhylhmia. 85 confirmed bv 
relemclry and Holler mon~lor ewmmsl~oin pelformed before hor- 
pi! al dircbarge. A followup Holler monitor esaminildon is “budned 
spproxim:ttely 2 10 4 wcekr arter ho+d discharge 10 denermine the 
long-fen &iC.lCy of the drug. We have been able 10 manage Ihe 
arrhythmias wilh initial doses or400 to SW mgfday wnh a mnmw 
nance dose of 2W muday. If the arrhythrme breaks through. 
additional incwmcnt\ or amiadarone are given. A Holler wdy (I 
obtaiaed approxim;ltely 5 day\ after the initiation of therapy or the 
initiation of the final change m dosage. If the arrhythmia is under 
conlrol, Ihe patient is discharged on lbat dose of Ihe drug lowally 
:vV m&&y). A! Ihe lime orfollow-up. irlbe arrbylhmis condnoes to 
be under control. the dosage is again decreased to IW mglduy. 
Thcraoeudc efficacv is xconfirmcd bv u subseauent H&r m&or 
2 weeks after the last change in do&. 
If side effects do develop during long-term followup. our ap- 
preach h-s been 10 reduce the dosage of the drug by approx,mately 
5@%. Confirma,iun “r E”ntr”l ol :hc arrbydlmia is demonarated 2 
weeks later by a repeat Hoher study. Utilizing lhn melhod. we have 
round very few incidents or side e~eclr with the use of small do\es 
0r amiodarone. 
Amiudarone il also extremely eflective in padents with conges- 
live bean failure and a mitral valve oroaberir. We have titrated an 
initial dose of 2CQ mglday down lb Ihe IOWCSL dose possible to 
conlrol the venucular response. The rewltad slowing of heart rate 
has caused an mcreax in diastolic filling period and we then place 
the padem on a maintenance dosage or ar little ar 100 m#3 dmer a 
week. We have also controlled the arrhylhmia orpatients uilhout a 
mitral valve pronhesis who had atrial fibrillation wilh a rapid 
ventricular response. In both sets of pelients the arrhythmia had 
oreviouslv been uncontrolled with dieoxin lheraov. We then used 
nf control or the r&id atrial Rbrill&n and obseived 
improvernerd in exercise lolersnce. We have also treated an elderly 
palienl who was bcdriddw with refmctory congerlive hean fadore 
but now lives indewendendv at home. If side ctTeclr dewloo. the 
atria1 arrhylbmls\. \re have found it of little benefit in pa!ienlr with 
congertive hean redore brwse 01 iIs negalive inotropic eRect. 
